GlassScriptPhysician profile
Carey J Welsh
NPI 1063413912
$4,592.19
in general payments reported to CMS, 2019-2025
25 companies · $658 in 2025
The $658 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $159 · 2020: $219 · 2021: $351 · 2022: $554 · 2023: $1,395 · 2024: $1,256 · 2025: $658.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,309.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,308.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $909.28 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $620.56 | 2019-2025 | Trelegy Ellipta, Arexvy, Bexsero |
| Novo Nordisk INC | $585.87 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $319.57 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $315.72 | 2021-2025 | Repatha, Otezla, Evenity |
| Abbvie INC. | $291.86 | 2022-2025 | Ubrelvy |
| Bayer Healthcare Pharmaceuticals INC. | $268.59 | 2022-2025 | |
| Sanofi Pasteur INC. | $250.37 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $172.56 | 2020-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $160.57 | 2019-2023 | Verquvo, Januvia, Segluromet |
| Exact Sciences Corporation | $147.35 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $83.18 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $65.05 | 2019-2024 | |
| Teva Pharmaceuticals USA, INC. | $57.69 | 2023-2025 | Austedo Xr, Austedo Xr |
| Verona Pharma, INC. | $56.67 | 2025 | Ohtuvayre |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $51.51 | 2023 | Azstarys |
| Sanofi-Aventis U.S. LLC | $48.70 | 2019-2021 | |
| Abbott Laboratories | $32.81 | 2024 | Id Now Instrument |
| Janssen Pharmaceuticals, INC | $29.80 | 2019 | |
| Astellas Pharma US INC | $26.71 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.40 | 2020 | |
| Genzyme Corporation | $25.12 | 2025 | |
| Hologic Sales and Service, LLC | $17.31 | 2023 | Thinprep 2000 Processor |
| Chiesi USA, INC. | $15.35 | 2024 | Elfabrio |
| Corcept Therapeutics | $13.59 | 2024 | Korlym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carey Welsh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.